PMID- 35114215
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20220531
IS  - 1096-0007 (Electronic)
IS  - 0014-4835 (Linking)
VI  - 217
DP  - 2022 Apr
TI  - Runx1 regulates Tff1 expression to expedite viability of retinal microvascular 
      endothelial cells in mice with diabetic retinopathy.
PG  - 108969
LID - S0014-4835(22)00050-1 [pii]
LID - 10.1016/j.exer.2022.108969 [doi]
AB  - Diabetic retinopathy (DR) represents a major complication of diabetes, and 
      molecular mechanisms related to vascular dysfunction, particularly endothelial 
      dysfunction, in DR remains unclear. In the present work, we generated a DR animal 
      model using mice and a cell model in mouse retinal microvascular endothelial 
      cells (mRMECs) to examine the role of Trefoil factor family 1 (Tff1) in DR. Tff1 
      was poorly expressed in DR mice and high glucose (HG)-treated mRMECs. 
      Overexpression of Tff1 significantly attenuated streptozotocin-induced retinal 
      proliferation and angiogenesis in DR mice and reduced the secretion of 
      inflammatory factors. In HG-treated mRMECs, overexpression of Tff1 remarkably 
      reduced the proliferation and angiogenesis of mRMECs. In further experiments, we 
      found that Tff1 was transcriptionally repressed by Runt-related transcription 
      factor 1 (Runx1) directly, and Tff1 expression was indirectly modulated by Runx1 
      via the core-binding factor subunit beta (CBF-beta)/nuclear factor, erythroid 
      2/microRNA-423-5p axis and the CBF-beta/estrogen receptor 1 (ESR1) axis. Moreover, 
      Tff1 could inhibit the activation of NF-kappaB signaling pathway, which in turn 
      attenuated retinal endothelial cell proliferation and angiogenesis. It was thus 
      proposed that Runx1/Tff1/NF-kappaB axis may be a potential target for the treatment 
      strategy of DR, and further studies are needed.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Ophthalmology, Shanxi Bethune Hospital, Shanxi Academy of Medical 
      Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 
      Taiyuan, 030012, Shanxi, PR China; Department of Ophthalmology, Tongji Hospital, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      430030, Hubei, PR China. Electronic address: zhangwei_332@126.com.
FAU - Zhang, Dingguo
AU  - Zhang D
AD  - Department of Cardiology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, 210029, Jiangsu, PR China.
FAU - Cheng, Yan
AU  - Cheng Y
AD  - Department of Nuclear Medicine, First Hospital of Shanxi Medical University, 
      Taiyuan, 030001, Shanxi, PR China.
FAU - Liang, Xing
AU  - Liang X
AD  - Department of Ophthalmology, Shanxi Bethune Hospital, Shanxi Academy of Medical 
      Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 
      Taiyuan, 030012, Shanxi, PR China.
FAU - Wang, Jingjing
AU  - Wang J
AD  - Department of Ophthalmology, Shanxi Bethune Hospital, Shanxi Academy of Medical 
      Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 
      Taiyuan, 030012, Shanxi, PR China.
LA  - eng
PT  - Journal Article
DEP - 20220131
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
RN  - 0 (Runx1 protein, mouse)
RN  - 0 (Tff1 protein, mouse)
RN  - 0 (Trefoil Factor-1)
SB  - IM
MH  - Animals
MH  - *Core Binding Factor Alpha 2 Subunit/metabolism
MH  - *Diabetes Mellitus/metabolism
MH  - *Diabetic Retinopathy/metabolism
MH  - Endothelial Cells/metabolism
MH  - Mice
MH  - *MicroRNAs/metabolism
MH  - NF-kappa B/metabolism
MH  - Neovascularization, Pathologic/metabolism
MH  - Retina/metabolism
MH  - *Trefoil Factor-1/metabolism
OTO - NOTNLM
OT  - Diabetic retinopathy
OT  - Mouse retinal microvascular endothelial cells
OT  - NF-kappaB signaling pathway
OT  - Runx1
OT  - Tff1
EDAT- 2022/02/04 06:00
MHDA- 2022/04/22 06:00
CRDT- 2022/02/03 20:12
PHST- 2021/09/14 00:00 [received]
PHST- 2022/01/25 00:00 [revised]
PHST- 2022/01/27 00:00 [accepted]
PHST- 2022/02/04 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
PHST- 2022/02/03 20:12 [entrez]
AID - S0014-4835(22)00050-1 [pii]
AID - 10.1016/j.exer.2022.108969 [doi]
PST - ppublish
SO  - Exp Eye Res. 2022 Apr;217:108969. doi: 10.1016/j.exer.2022.108969. Epub 2022 Jan 
      31.